Nippon India Mutual Fund · Direct Growth · SEBI Category: Equity
Nippon India Pharma Fund is India's largest pharmaceutical sector fund by AUM — a position built through consistent performance and Sailesh Bhan's 20+ year specialist expertise in the sector. The fund invests in pharmaceutical manufacturers, API (Active Pharmaceutical Ingredient) makers, hospital chains, diagnostic companies and specialty chemical companies with pharma linkages.
The fund has lived through multiple US FDA import alert cycles — understanding when regulatory risk is overpriced versus genuinely existential for a company. Bhan's long sector tenure means the fund has managed through India's most challenging pharma regulatory periods (2015-2018 FDA actions) and delivered strong performance during the post-COVID pharma rerating and the current specialty pharma growth cycle.
Sailesh Raj Bhan is Deputy CIO at Nippon India Mutual Fund and has been co-managing Nippon India Pharma Fund since 2004 — one of the longest continuous tenures managing a pharmaceutical sector fund in India. He co-manages with Dhrumil Shah. Bhan's 20-year deep sector expertise — understanding FDA regulatory dynamics, drug pricing in US markets and domestic formulation business models — is a key differentiator for this fund.
For current co-manager details and full biography, refer to the latest Nippon India Mutual Fund factsheet on AMFI or the AMC website.
Informational points to help you form your own view — not judgements or recommendations.
Live data. Current fund highlighted. Click any fund name for full analysis.
| Fund | NAV | AAUM | 1Y Return | 3Y CAGR | 5Y CAGR | Sharpe (3Y) |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund ▲ | ₹619.81 | ₹7.9K Cr Jan–Mar 2026 | +6.5% | +21.6% p.a. | +13.7% p.a. | 1.44 |
| SBI Healthcare Opportunities Fund | ₹560.52 | ₹3.8K Cr Jan–Mar 2026 | +12.2% | +24.8% p.a. | +17.1% p.a. | 1.59 |
| DSP Healthcare Fund | ₹47.53 | ₹3.0K Cr Jan–Mar 2026 | +8.9% | +22.4% p.a. | +15.6% p.a. | 1.53 |
| Mirae Asset Healthcare Fund | ₹48.56 | ₹2.7K Cr Jan–Mar 2026 | +13.2% | +24.9% p.a. | +15.7% p.a. | 1.56 |
| HDFC Pharma and Healthcare Fund | ₹20.81 | ₹1.9K Cr Jan–Mar 2026 | +20.0% | — | — | — |
Calculated from 2,580 daily NAV records in RightAdvise DB. Last calculated: Jun 2026.
1M / 3M / 6M / 1Y — simple point-to-point return · 3Y / 5Y / 10Y — CAGR (compounded annual growth rate)
Based on all rolling windows in full NAV history. Dates show the start and end of each period.
Jan 1 to Dec 31 each year. Simple point-to-point — not CAGR.
Rolling returns show performance across every possible investment start date — not one cherry-picked number. Learn more →
How much the fund fell from its peak NAV — what investors actually experience during crashes. Calculated from full NAV history.
Calculated from actual NAV data. "Pre-inception" means the fund didn't exist during that period.
Calculated from 3 years of daily NAV — industry standard. Risk-free rate: 6.5% p.a. Last updated: Jun 2026. What do these mean? →
Our portfolio holdings page shows every stock the fund owns, sector allocation, and month-over-month changes — from official AMC disclosures.
See how Nippon India Pharma FundGrowth PlanOption ranks against other Equity funds on returns, drawdown, Sharpe ratio and AAUM — side by side.
New fund analysis, articles and market insights — no spam, no selling. Unsubscribe anytime.
Found this useful? Share it
Found an error? Have a suggestion? We read every response.